drugset
drugset / Trial / NCT01358162

Phase IC Study of Safety and PK of SQ109 300mg Daily

NCT01358162 ↗

Phase 1 Completed 10 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
RandomizedParallel-groupTriple-blindTreatment

Summary

Healthy male and female volunteers will be given SQ109 300mg daily for 14 days to assess the safety and tolerability and pharmacokinetics.

Timeline

Start
2010-11
Primary completion
2011-02
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SQ109 Small molecule 300 mg Oral

Indications

tuberculosis